Characteristics
|
Total (N = 211)
|
QRS duration > 160 ms
(N = 82)
|
QRS duration < 160 ms
(N = 129)
|
p-value
|
Male sex |
124 (58.8) |
58 (70.7) |
66 (51.2) |
0.006 |
Age (years) |
66 ± 12 |
67 ± 10 |
66 ± 13 |
0.287 |
Baseline ECG (ms) |
85.0 ± 7.5 |
88.2 ± 7.5 |
83.0 ± 6.8 |
<
0.01 |
Atrial fibrillation |
181 (85.8) |
75 (91.5) |
106 (82.2) |
0.007 |
Hypertension |
108 (51.2) |
52 (63.4) |
56 (43.4) |
0.005 |
Heart Failure |
27 (12.8) |
15 (18.3) |
12 (9.3) |
0.089 |
Ischemic cardiomyopathy |
11 (5.2) |
6 (7.3) |
5 (3.9) |
0.344 |
LVEF (%) |
61.7 ± 10.6 |
59.9 ±12.2 |
62.9 ± 9.3 |
0.055 |
LVEDV (ml) |
106.8 ± 35.0 |
121.7 ± 39.8 |
97.4 ± 27.9 |
<
0.01 |
LVESV (ml) |
43.0 ± 26.2 |
51.9 ± 34.1 |
37.3 ± 17.4 |
0.01 |
IVST (mm) |
10.1 ± 2.7 |
10.6 ± 2.2 |
9.8 ± 3.0 |
0.046 |
PWT (mm) |
10.1 ± 6.8 |
10.0 ± 1.6 |
10.2 ± 8.6 |
0.782 |
LAD (mm) |
38.3 ± 7.3 |
42.1 ± 6.1 |
36.7 ± 7.2 |
<
0.01 |
E/e’ |
13.2 ± 6.5 |
15.9 ± 7.6 |
11.5 ± 4.9 |
<
0.01 |
β blocker use |
73 (34.6) |
37 (45.1) |
36 (27.9) |
0.012 |